IPA Stock Overview
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally.
ImmunoPrecise Antibodies Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CA$5.22|
|52 Week High||CA$8.81|
|52 Week Low||CA$4.52|
|1 Month Change||-29.74%|
|3 Month Change||6.97%|
|1 Year Change||-33.84%|
|3 Year Change||126.96%|
|5 Year Change||13.48%|
|Change since IPO||-19.07%|
Recent News & Updates
|IPA||CA Life Sciences||CA Market|
Return vs Industry: IPA underperformed the Canadian Life Sciences industry which returned -32.7% over the past year.
Return vs Market: IPA underperformed the Canadian Market which returned -7.3% over the past year.
|IPA Average Weekly Movement||9.8%|
|Life Sciences Industry Average Movement||9.8%|
|Market Average Movement||9.8%|
|10% most volatile stocks in CA Market||18.1%|
|10% least volatile stocks in CA Market||3.8%|
Stable Share Price: IPA is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: IPA's weekly volatility (10%) has been stable over the past year.
About the Company
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its contract research organization services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.
ImmunoPrecise Antibodies Fundamentals Summary
|IPA fundamental statistics|
Is IPA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IPA income statement (TTM)|
|Cost of Revenue||CA$8.70m|
Last Reported Earnings
Jul 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.92|
|Net Profit Margin||-117.44%|
How did IPA perform over the long term?See historical performance and comparison
Is IPA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for IPA?
Other financial metrics that can be useful for relative valuation.
|What is IPA's n/a Ratio?|
Price to Sales Ratio vs Peers
How does IPA's PS Ratio compare to its peers?
|IPA PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
DOSE Rapid Dose Therapeutics
GDNS Goodness Growth Holdings
IPA ImmunoPrecise Antibodies
Price-To-Sales vs Peers: IPA is expensive based on its Price-To-Sales Ratio (6.7x) compared to the peer average (5.2x).
Price to Earnings Ratio vs Industry
How does IPA's PE Ratio compare vs other companies in the North American Life Sciences Industry?
Price-To-Sales vs Industry: IPA is expensive based on its Price-To-Sales Ratio (6.7x) compared to the North American Life Sciences industry average (4.1x)
Price to Sales Ratio vs Fair Ratio
What is IPA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||6.7x|
|Fair PS Ratio||n/a|
Price-To-Sales vs Fair Ratio: Insufficient data to calculate IPA's Price-To-Sales Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of IPA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate IPA's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate IPA's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is ImmunoPrecise Antibodies forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as ImmunoPrecise Antibodies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine ImmunoPrecise Antibodies's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- ImmunoPrecise Antibodies competitive advantages and company strategy can generally be found in its financial reports archived here.
How has ImmunoPrecise Antibodies performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IPA is currently unprofitable.
Growing Profit Margin: IPA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IPA is unprofitable, and losses have increased over the past 5 years at a rate of 25.6% per year.
Accelerating Growth: Unable to compare IPA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IPA is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (15.3%).
Return on Equity
High ROE: IPA has a negative Return on Equity (-34.51%), as it is currently unprofitable.
Discover strong past performing companies
How is ImmunoPrecise Antibodies's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: IPA's short term assets (CA$27.1M) exceed its short term liabilities (CA$5.4M).
Long Term Liabilities: IPA's short term assets (CA$27.1M) exceed its long term liabilities (CA$8.3M).
Debt to Equity History and Analysis
Debt Level: IPA is debt free.
Reducing Debt: IPA had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IPA has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: IPA has less than a year of cash runway if free cash flow continues to reduce at historical rates of 36% each year
Discover healthy companies
What is ImmunoPrecise Antibodies's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|ImmunoPrecise Antibodies Dividend Yield vs Market|
|Company (ImmunoPrecise Antibodies)||n/a|
|Market Bottom 25% (CA)||2.1%|
|Market Top 25% (CA)||6.1%|
|Industry Average (Life Sciences)||0.3%|
|Analyst forecast in 3 Years (ImmunoPrecise Antibodies)||n/a|
Notable Dividend: Unable to evaluate IPA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IPA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IPA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IPA's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as IPA has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. Jennifer Lynne Bath, Ph D, has been the Chief Executive Officer and President of ImmunoPrecise Antibodies Ltd. since February 21, 2018.Dr. Bath served as the Global Director of Client Relations at Ald...
CEO Compensation Analysis
|Jennifer Bath's Compensation vs ImmunoPrecise Antibodies Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jul 31 2022||n/a||n/a|
|Apr 30 2022||n/a||n/a|
|Jan 31 2022||n/a||n/a|
|Oct 31 2021||n/a||n/a|
|Jul 31 2021||n/a||n/a|
|Apr 30 2021||CA$2m||CA$503k|
|Jan 31 2021||n/a||n/a|
|Oct 31 2020||n/a||n/a|
|Jul 31 2020||n/a||n/a|
|Apr 30 2020||CA$693k||CA$488k|
|Jan 31 2020||n/a||n/a|
|Oct 31 2019||n/a||n/a|
|Jul 31 2019||n/a||n/a|
|Apr 30 2019||CA$1m||CA$505k|
|Jan 31 2019||n/a||n/a|
|Oct 31 2018||n/a||n/a|
|Jul 31 2018||n/a||n/a|
|Apr 30 2018||CA$65k||CA$65k|
Compensation vs Market: Jennifer's total compensation ($USD1.68M) is above average for companies of similar size in the Canadian market ($USD177.09K).
Compensation vs Earnings: Jennifer's compensation has increased whilst the company is unprofitable.
Experienced Management: IPA's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Experienced Board: IPA's board of directors are considered experienced (4.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: IPA insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
|15 Sep 22||BuyCA$20,236||Jennifer Bath||Individual||3,100||CA$6.60|
|15 Sep 22||BuyCA$26,276||Brad McConn||Individual||4,000||CA$6.57|
|17 Aug 22||BuyCA$8,045||Jennifer Bath||Individual||1,100||CA$7.53|
|17 Aug 22||BuyCA$7,310||Robert Burke||Individual||1,000||CA$7.31|
|15 Aug 22||BuyCA$34,670||Gregory Smith||Individual||5,000||CA$6.93|
|15 Aug 22||BuyCA$3,436||Republique Capital||Company||500||CA$6.92|
|15 Aug 22||BuyCA$33,824||Jennifer Bath||Individual||5,000||CA$7.20|
|12 Aug 22||BuyCA$13,762||Republique Capital||Company||2,000||CA$7.19|
|10 Aug 22||BuyCA$22,711||Republique Capital||Company||4,000||CA$5.75|
|09 Aug 22||BuyCA$6,019||Jennifer Bath||Individual||1,100||CA$5.61|
|05 Aug 22||BuyCA$2,886||Jennifer Bath||Individual||550||CA$5.28|
|03 Aug 22||BuyCA$12,115||Jennifer Bath||Individual||2,290||CA$5.78|
|01 Aug 22||BuyCA$13,071||Ilse Roodink||Individual||2,400||CA$5.57|
|12 May 22||BuyCA$29,117||Republique Capital||Company||5,000||CA$6.05|
|11 May 22||BuyCA$287||Jennifer Bath||Individual||50||CA$5.73|
|09 May 22||BuyCA$8,005||Jennifer Bath||Individual||1,300||CA$6.23|
|05 May 22||BuyCA$2,658||Jennifer Bath||Individual||373||CA$7.24|
|29 Apr 22||BuyCA$2,669||Jennifer Bath||Individual||375||CA$7.15|
|27 Apr 22||BuyCA$1,791||Jennifer Bath||Individual||250||CA$7.17|
|22 Apr 22||BuyCA$6,023||Jennifer Bath||Individual||830||CA$7.33|
|14 Apr 22||BuyCA$36,250||Republique Capital||Company||5,000||CA$7.25|
|13 Apr 22||BuyCA$8,553,850||Ingrid Brands||Individual||1,565,865||CA$5.46|
|13 Apr 22||BuyCA$8,553,850||Dirk Van Hyfte||Individual||1,565,865||CA$5.46|
|12 Apr 22||BuyCA$5,778||Jennifer Bath||Individual||800||CA$7.36|
|11 Apr 22||BuyCA$8,043||Jennifer Bath||Individual||1,100||CA$7.40|
|11 Apr 22||BuyCA$6,801||Ilse Roodink||Individual||942||CA$7.22|
|11 Apr 22||BuyCA$72,244||Republique Capital||Company||10,000||CA$7.30|
|11 Apr 22||BuyCA$2,230||Jennifer Bath||Individual||300||CA$7.43|
|07 Apr 22||BuyCA$4,895||Barry Duplantis||Individual||700||CA$7.00|
|06 Apr 22||BuyCA$9,172||Jennifer Bath||Individual||1,290||CA$7.20|
|06 Apr 22||BuyCA$74,958||Carla Dahl||Individual||10,000||CA$7.50|
|05 Apr 22||BuyCA$22,470||Gregory Smith||Individual||3,000||CA$7.49|
|04 Apr 22||BuyCA$69,359||Republique Capital||Company||9,900||CA$7.07|
|01 Apr 22||BuyCA$6,613||Brad McConn||Individual||1,000||CA$6.62|
|01 Apr 22||BuyCA$3,407||Jennifer Bath||Individual||530||CA$6.49|
|31 Mar 22||BuyCA$18,689||Brad McConn||Individual||3,000||CA$6.23|
|31 Mar 22||BuyCA$3,132||Jennifer Bath||Individual||500||CA$6.42|
|30 Mar 22||BuyCA$57,990||Republique Capital||Company||10,000||CA$6.20|
|30 Mar 22||BuyCA$21,489||Jennifer Bath||Individual||3,600||CA$6.23|
|16 Feb 22||BuyCA$20,391||Jennifer Bath||Individual||3,150||CA$6.47|
|11 Feb 22||BuyCA$4,042||Jennifer Bath||Individual||600||CA$6.78|
|09 Feb 22||BuyCA$10,246||Jennifer Bath||Individual||1,500||CA$6.84|
|09 Feb 22||BuyCA$20,547||Frederic Chabot||Individual||3,000||CA$6.85|
|11 Jan 22||BuyCA$14,498||Jennifer Bath||Individual||1,900||CA$7.63|
|30 Dec 21||BuyCA$14,811||Jennifer Bath||Individual||2,100||CA$7.07|
|29 Dec 21||BuyCA$18,833||Jennifer Bath||Individual||2,700||CA$6.99|
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 28.4%.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
ImmunoPrecise Antibodies Ltd.'s employee growth, exchange listings and data sources
- Name: ImmunoPrecise Antibodies Ltd.
- Ticker: IPA
- Exchange: TSXV
- Founded: 1983
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: CA$129.648m
- Shares outstanding: 24.84m
- Website: https://www.ipatherapeutics.com
Number of Employees
- ImmunoPrecise Antibodies Ltd.
- 3204–4464 Markham Street
- British Columbia
- V8Z 7X8
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|IPA||TSXV (TSX Venture Exchange)||Yes||Common Shares||CA||CAD||Dec 2016|
|IPA||NasdaqGM (Nasdaq Global Market)||Yes||Common Shares||US||USD||Dec 2016|
|TQB||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Dec 2016|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/28 00:00|
|End of Day Share Price||2022/09/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.